Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing therapeutics for liver and respiratory rare diseases, as well as infectious disease vaccines. It leverages proprietary LUNAR lipid-mediated delivery and STARR self-amplifying mRNA platforms to advance its pipeline. Key internal programs include ARCT-810 for ornithine transcarbamylase deficiency and ARCT-032, an inhaled mRNA therapy for cystic fibrosis, both in Phase 2 clinical studies targeting severe patient populations. In vaccines, it partners with CSL Seqirus on mRNA candidates for COVID-19, influenza, and other infectious diseases, with KOSTAIVE approved in Japan, the EU, and the UK, generating initial commercial sales through collaborators like Meiji and CSL Seqirus. The company operates in a single business segment encompassing discovery, development, and commercialization of mRNA medicines. Founded in 2013 and headquartered in San Diego, California, Arcturus Therapeutics Holdings Inc. plays a significant role in the biotech sector by pioneering mRNA technologies for rare diseases and partnered vaccine franchises.